Cargando…

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults

OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected...

Descripción completa

Detalles Bibliográficos
Autores principales: Byakika-Kibwika, Pauline, Lamorde, Mohammed, Mayito, Jonathan, Nabukeera, Lillian, Namakula, Rhoda, Mayanja-Kizza, Harriet, Katabira, Elly, Ntale, Muhammad, Pakker, Nadine, Ryan, Mairin, Hanpithakpong, Warunee, Tarning, Joel, Lindegardh, Niklas, de Vries, Peter J., Khoo, Saye, Back, David, Merry, Concepta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465101/
https://www.ncbi.nlm.nih.gov/pubmed/22687893
http://dx.doi.org/10.1093/jac/dks207
_version_ 1782245506217410560
author Byakika-Kibwika, Pauline
Lamorde, Mohammed
Mayito, Jonathan
Nabukeera, Lillian
Namakula, Rhoda
Mayanja-Kizza, Harriet
Katabira, Elly
Ntale, Muhammad
Pakker, Nadine
Ryan, Mairin
Hanpithakpong, Warunee
Tarning, Joel
Lindegardh, Niklas
de Vries, Peter J.
Khoo, Saye
Back, David
Merry, Concepta
author_facet Byakika-Kibwika, Pauline
Lamorde, Mohammed
Mayito, Jonathan
Nabukeera, Lillian
Namakula, Rhoda
Mayanja-Kizza, Harriet
Katabira, Elly
Ntale, Muhammad
Pakker, Nadine
Ryan, Mairin
Hanpithakpong, Warunee
Tarning, Joel
Lindegardh, Niklas
de Vries, Peter J.
Khoo, Saye
Back, David
Merry, Concepta
author_sort Byakika-Kibwika, Pauline
collection PubMed
description OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected adults received standard six-dose artemether/lumefantrine 80/480 mg before and at efavirenz or nevirapine steady state. Artemether, dihydroartemisinin, lumefantrine, efavirenz and nevirapine plasma concentrations were measured and compared. RESULTS: Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01). Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01). Lumefantrine C(max) and AUC were non-significantly reduced by nevirapine. Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure. CONCLUSIONS: Co-administration of artemether/lumefantrine with efavirenz or nevirapine resulted in a reduction in artemether, dihydroartemisinin, lumefantrine and nevirapine exposure. These drug interactions may increase the risk of malaria treatment failure and development of resistance to artemether/lumefantrine and nevirapine. Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed.
format Online
Article
Text
id pubmed-3465101
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-34651012012-10-07 Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults Byakika-Kibwika, Pauline Lamorde, Mohammed Mayito, Jonathan Nabukeera, Lillian Namakula, Rhoda Mayanja-Kizza, Harriet Katabira, Elly Ntale, Muhammad Pakker, Nadine Ryan, Mairin Hanpithakpong, Warunee Tarning, Joel Lindegardh, Niklas de Vries, Peter J. Khoo, Saye Back, David Merry, Concepta J Antimicrob Chemother Original Research OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected adults received standard six-dose artemether/lumefantrine 80/480 mg before and at efavirenz or nevirapine steady state. Artemether, dihydroartemisinin, lumefantrine, efavirenz and nevirapine plasma concentrations were measured and compared. RESULTS: Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01). Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01). Lumefantrine C(max) and AUC were non-significantly reduced by nevirapine. Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure. CONCLUSIONS: Co-administration of artemether/lumefantrine with efavirenz or nevirapine resulted in a reduction in artemether, dihydroartemisinin, lumefantrine and nevirapine exposure. These drug interactions may increase the risk of malaria treatment failure and development of resistance to artemether/lumefantrine and nevirapine. Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed. Oxford University Press 2012-09 2012-06-11 /pmc/articles/PMC3465101/ /pubmed/22687893 http://dx.doi.org/10.1093/jac/dks207 Text en © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Byakika-Kibwika, Pauline
Lamorde, Mohammed
Mayito, Jonathan
Nabukeera, Lillian
Namakula, Rhoda
Mayanja-Kizza, Harriet
Katabira, Elly
Ntale, Muhammad
Pakker, Nadine
Ryan, Mairin
Hanpithakpong, Warunee
Tarning, Joel
Lindegardh, Niklas
de Vries, Peter J.
Khoo, Saye
Back, David
Merry, Concepta
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title_full Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title_fullStr Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title_full_unstemmed Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title_short Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
title_sort significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in hiv-infected ugandan adults
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465101/
https://www.ncbi.nlm.nih.gov/pubmed/22687893
http://dx.doi.org/10.1093/jac/dks207
work_keys_str_mv AT byakikakibwikapauline significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT lamordemohammed significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT mayitojonathan significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT nabukeeralillian significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT namakularhoda significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT mayanjakizzaharriet significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT katabiraelly significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT ntalemuhammad significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT pakkernadine significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT ryanmairin significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT hanpithakpongwarunee significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT tarningjoel significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT lindegardhniklas significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT devriespeterj significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT khoosaye significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT backdavid significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults
AT merryconcepta significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults